Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343952 · ClinicalTrials.gov registry record · Phase 2
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
A Phase 2 study, sponsored by Nasser Hanna, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT02343952 is a Phase 2 study that has completed, run by Nasser Hanna, M.D.. The registered enrollment target is 93 participants.
The verdict
NCT02343952, a Phase 2 study, has completed, sponsored by Nasser Hanna, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2015-03-09 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02343952
The ClinicalTrials.gov registry entry for NCT02343952 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nasser Hanna, M.D., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02343952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02343952 about?
NCT02343952 is a clinical study titled "Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC". This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.
What is the current status of trial NCT02343952?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2015-03-09. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT02343952?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02343952?
This trial is sponsored by Nasser Hanna, M.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.